Selected research
Industry Research
Antidiabetic SGLT-2 Inhibitor Industry Research Report 2026
Market perspective
The global Antidiabetic SGLT-2 Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antidiabetic SGLT-2 Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antidiabetic SGLT-2 Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antidiabetic SGLT-2 Inhibitor include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antidiabetic SGLT-2 Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antidiabetic SGLT-2 Inhibitor Market by Company
Boehringer Ingelheim
Bristol-Myers Squibb
Novo Nordisk
Servier Laboratories
AstraZeneca
GlaxoSmithKline
Pfizer
Eli Lilly
Merck & Co
Johnson & Johnson
Sanofi
Takeda Pharmaceuticals
Antidiabetic SGLT-2 Inhibitor Segment by Type
Canagliflozin
Dapagliflozin
Empagliflozin
Other
Antidiabetic SGLT-2 Inhibitor Segment by Application
Hospitals
Clinics
Other
Antidiabetic SGLT-2 Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic SGLT-2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic SGLT-2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic SGLT-2 Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antidiabetic SGLT-2 Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antidiabetic SGLT-2 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- Other
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Novo Nordisk
- Servier Laboratories
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Merck & Co
- Johnson & Johnson
- Sanofi
- Takeda Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size (2021-2032)
- 2.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales (2021-2032)
- 2.2.3 Global Antidiabetic SGLT-2 Inhibitor Market Average Price (2021-2032)
- 2.3 Antidiabetic SGLT-2 Inhibitor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Canagliflozin
- 2.3.3 Dapagliflozin
- 2.3.4 Empagliflozin
- 2.3.5 Other
- 2.4 Antidiabetic SGLT-2 Inhibitor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antidiabetic SGLT-2 Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antidiabetic SGLT-2 Inhibitor Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antidiabetic SGLT-2 Inhibitor Revenue of Manufacturers (2021-2026)
- 3.4 Global Antidiabetic SGLT-2 Inhibitor Average Price by Manufacturers (2021-2026)
- 3.5 Global Antidiabetic SGLT-2 Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antidiabetic SGLT-2 Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antidiabetic SGLT-2 Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of Antidiabetic SGLT-2 Inhibitor, Established Date
- 3.9 Global Antidiabetic SGLT-2 Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer Ingelheim
- 4.1.1 Boehringer Ingelheim Company Information
- 4.1.2 Boehringer Ingelheim Business Overview
- 4.1.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.1.5 Boehringer Ingelheim Recent Developments
- 4.2 Bristol-Myers Squibb
- 4.2.1 Bristol-Myers Squibb Company Information
- 4.2.2 Bristol-Myers Squibb Business Overview
- 4.2.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.2.5 Bristol-Myers Squibb Recent Developments
- 4.3 Novo Nordisk
- 4.3.1 Novo Nordisk Company Information
- 4.3.2 Novo Nordisk Business Overview
- 4.3.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.3.5 Novo Nordisk Recent Developments
- 4.4 Servier Laboratories
- 4.4.1 Servier Laboratories Company Information
- 4.4.2 Servier Laboratories Business Overview
- 4.4.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.4.5 Servier Laboratories Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Merck & Co
- 4.9.1 Merck & Co Company Information
- 4.9.2 Merck & Co Business Overview
- 4.9.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.9.5 Merck & Co Recent Developments
- 4.10 Johnson & Johnson
- 4.10.1 Johnson & Johnson Company Information
- 4.10.2 Johnson & Johnson Business Overview
- 4.10.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.10.5 Johnson & Johnson Recent Developments
- 4.11 Sanofi
- 4.11.1 Sanofi Company Information
- 4.11.2 Sanofi Business Overview
- 4.11.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.11.5 Sanofi Recent Developments
- 4.12 Takeda Pharmaceuticals
- 4.12.1 Takeda Pharmaceuticals Company Information
- 4.12.2 Takeda Pharmaceuticals Business Overview
- 4.12.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio
- 4.12.5 Takeda Pharmaceuticals Recent Developments
5 Global Antidiabetic SGLT-2 Inhibitor Market Scenario by Region
- 5.1 Global Antidiabetic SGLT-2 Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021-2032
- 5.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021-2026
- 5.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2027-2032
- 5.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2021-2032
- 5.3.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2021-2026
- 5.3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2027-2032
- 5.4 North America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
- 5.4.1 North America Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
- 5.4.3 North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
- 5.5.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
- 5.5.3 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
- 5.7.1 South America Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
- 5.7.3 South America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
- 6.1.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2032)
- 6.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
- 6.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2032)
- 6.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
- 7.1.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2032)
- 7.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
- 7.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2032)
- 7.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antidiabetic SGLT-2 Inhibitor Value Chain Analysis
- 8.1.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
- 8.2 Antidiabetic SGLT-2 Inhibitor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antidiabetic SGLT-2 Inhibitor Distributors
- 8.2.3 Antidiabetic SGLT-2 Inhibitor Customers
9 Global Antidiabetic SGLT-2 Inhibitor Analyzing Market Dynamics
- 9.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
- 9.2 Antidiabetic SGLT-2 Inhibitor Industry Drivers
- 9.3 Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges
- 9.4 Antidiabetic SGLT-2 Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst